BioSpace News Archive

FDA

U.S. FDA Grants Fast Track Designation to TARIS® for TAR-200 (GemRIS™) in Muscle Invasive Bladder Cancer

Designation for Patients Unfit for Curative Intent Therapy

April 3, 2018
·
2 min read
Job Trends

MetaBank® Announces Partnership with Health Credit Services to Originate Personal Healthcare Loans

Partnership is part of MetaBank’s continued investment in consumer lending via its total solution platform for marketplace lending

April 3, 2018
·
4 min read
Genetown

Rapid Mycoplasma Testing Method Now Accepted by Regulators for QA/QC and Lot Release

MycoSEQ Mycoplasma Detection Method can accelerate production timelines for manufacturers of cell and gene therapies, biotherapeutics, vaccines and other cell-culture-based modalities

April 3, 2018
·
3 min read
Dermavant Expands Pipeline and Strengthens Executive Team with Key Hires

Dermavant Sciences announced that it has expanded its pipeline by in-licensing an investigational drug for the treatment of multi-focal hyperhidrosis.

April 3, 2018
·
5 min read
Biotech Beach

Axonics® Announces $40 Million Financing

Equity Round of $20 million led by Longitude Capital with Silicon Valley Bank Providing a $20 million Credit Facility

April 3, 2018
·
3 min read
Deals

Boston Scientific Announces Acquisition of Securus Medical Group, Inc.

Acquisition strengthens electrophysiology cardiac ablation portfolio with thermal monitor

April 3, 2018
·
7 min read
GeneNews Announces Q4 and Year End 2017 Financial Results & Provides Progress Update

GeneNews Limited announced operational and financial results for the three- and twelve-month periods ended December 31, 2017, and provided a progress update on its business.

April 3, 2018
·
3 min read
FDA

US FDA Accepts Biologics License Application for Moxetumomab Pasudotox in Hairy Cell Leukemia

Moxetumomab pasudotox BLA granted Priority Review

April 3, 2018
·
6 min read
MIXiii-BIOMED 2018: Introducing the Best of Israel’s Life Science Innovations

Israel’s 17th national life science and technology week to be held on May 15-17, 2018 at the David InterContinental Hotel in Tel Aviv

April 3, 2018
·
3 min read
Drug Development

Palatin Technologies Presents Preclinical Oral Formulation Data on PL-8177, An Investigational Melanocortin Receptor 1 Agonist for Inflammatory Bowel Diseases

PL-8177 is Palatin’s lead clinical development candidate for ulcerative colitis and other inflammatory bowel diseases.

April 3, 2018
·
4 min read